

Panitumumab 20050181 study

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Panitumumab 20050181 study

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: Second-line treatment of patients with wild-type RAS mCRC who have received first-line fluoropyrimidine-based ChT (excluding irinotecan)

Experimental Arm: Panitumumab + FOLFIRI (folinic acid, 5-fluorouracil, irinotecan)

Control Arm: FOLFIRI (folinic acid, 5-fluorouracil, irinotecan)

